INS and type 2 diabetes mellitus: The utilization of BBI was generally higher in the historical control period extension group compared to the pilot phase of the study, but the overall use of BBI during the eight-month extension was significantly higher during the pocket insulin dosing guide intervention (24.7% vs. 44.7% control vs. intervention, P < 0.01). For the entire 12-month evaluation period, BBI utilization for type-2 diabetes management was 16.7% during the control period and 41.9% after the introduction of the pocket insulin dosing guide (P < 0.01).